Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
19 05 2020
19 05 2020
Historique:
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
4
6
2020
Statut:
ppublish
Résumé
The benefit of blood pressure lowering for the prevention of dementia or cognitive impairment is unclear. To determine the association of blood pressure lowering with dementia or cognitive impairment. Search of PubMed, EMBASE, and CENTRAL for randomized clinical trials published from database inception through December 31, 2019, that evaluated the association of blood pressure lowering on cognitive outcomes. The control groups consisted of either placebo, alternative antihypertensive agents, or higher blood pressure targets. Data were screened and extracted independently by 2 authors. Random-effects meta-analysis models were used to report pooled treatment effects and CIs. The primary outcome was dementia or cognitive impairment. The secondary outcomes were cognitive decline and changes in cognitive test scores. Fourteen randomized clinical trials were eligible for inclusion (96 158 participants), of which 12 reported the incidence of dementia (or composite of dementia and cognitive impairment [3 trials]) on follow-up and were included in the primary meta-analysis, 8 reported cognitive decline, and 8 reported changes in cognitive test scores. The mean (SD) age of trial participants was 69 (5.4) years and 40 617 (42.2%) were women. The mean systolic baseline blood pressure was 154 (14.9) mm Hg and the mean diastolic blood pressure was 83.3 (9.9) mm Hg. The mean duration of follow-up was 49.2 months. Blood pressure lowering with antihypertensive agents compared with control was significantly associated with a reduced risk of dementia or cognitive impairment (12 trials; 92 135 participants) (7.0% vs 7.5% of patients over a mean trial follow-up of 4.1 years; odds ratio [OR], 0.93 [95% CI, 0.88-0.98]; absolute risk reduction, 0.39% [95% CI, 0.09%-0.68%]; I2 = 0.0%) and cognitive decline (8 trials) (20.2% vs 21.1% of participants over a mean trial follow-up of 4.1 years; OR, 0.93 [95% CI, 0.88-0.99]; absolute risk reduction, 0.71% [95% CI, 0.19%-1.2%]; I2 = 36.1%). Blood pressure lowering was not significantly associated with a change in cognitive test scores. In this meta-analysis of randomized clinical trials, blood pressure lowering with antihypertensive agents compared with control was significantly associated with a lower risk of incident dementia or cognitive impairment.
Identifiants
pubmed: 32427305
pii: 2766163
doi: 10.1001/jama.2020.4249
pmc: PMC7237983
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1934-1944Subventions
Organisme : Chief Scientist Office
ID : SCAF/17/01
Pays : United Kingdom
Organisme : European Research Council
Pays : International
Commentaires et corrections
Type : CommentIn
Références
BMJ. 2011 Aug 30;343:d4829
pubmed: 21878462
JAMA. 2019 Aug 13;322(6):524-534
pubmed: 31408137
Neurology. 2002 Apr 23;58(8):1175-81
pubmed: 11971083
J Stroke. 2015 Sep;17(3):302-11
pubmed: 26437995
Diabetologia. 2009 Nov;52(11):2328-2336
pubmed: 19688336
BMJ. 1996 Mar 30;312(7034):801-5
pubmed: 8608285
Arch Intern Med. 2002 Oct 14;162(18):2046-52
pubmed: 12374512
J Hypertens. 2013 Jun;31(6):1073-82
pubmed: 23552124
J Hypertens. 2018 Sep;36(9):1780-1787
pubmed: 29927845
Arch Intern Med. 1994 Oct 10;154(19):2154-60
pubmed: 7944835
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Lancet Neurol. 2008 Oct;7(10):875-84
pubmed: 18757238
Arch Intern Med. 2003 May 12;163(9):1069-75
pubmed: 12742805
Age Ageing. 2020 Feb 27;49(2):154-160
pubmed: 31830268
BMJ. 2010 Mar 30;340:c117
pubmed: 20354011
JAMA. 2019 Feb 12;321(6):553-561
pubmed: 30688979
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004034
pubmed: 19821318
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Neurology. 2005 Jan 25;64(2):277-81
pubmed: 15668425
Lancet Neurol. 2011 Jan;10(1):43-53
pubmed: 20980201
Neurology. 2019 May 21;92(21):1017-1018
pubmed: 31019101
Neurobiol Aging. 2000 Jan-Feb;21(1):49-55
pubmed: 10794848
Lancet Neurol. 2014 Dec;13(12):1177-85
pubmed: 25453457
BMJ. 2003 Jan 25;326(7382):219
pubmed: 12543843
Lancet. 1996 Apr 27;347(9009):1141-5
pubmed: 8609748
Neurology. 2019 Mar 26;92(13):e1435-e1446
pubmed: 30814321
Lancet Neurol. 2014 Aug;13(8):788-94
pubmed: 25030513
Lancet Neurol. 2008 Aug;7(8):683-9
pubmed: 18614402
Lancet Glob Health. 2019 May;7(5):e596-e603
pubmed: 31000129
J Hypertens. 2003 May;21(5):875-86
pubmed: 12714861
Eur Heart J. 2018 Sep 1;39(33):3119-3125
pubmed: 29901708
J Clin Epidemiol. 2019 Jul;111:32-40
pubmed: 30940600
Cochrane Database Syst Rev. 2018 Jul 19;7:CD007858
pubmed: 30024023
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
JAMA Intern Med. 2014 Mar;174(3):324-33
pubmed: 24493100